Pre-Open Stock Movers 10/25: (SAEX) (CWEI) (SWFT) Higher; (DPRX) (CRBP) (UA) Lower (more...)

October 25, 2016 9:05 AM EDT

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Pre-Open Stock Movers

Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX) 84.7% LOWER; announced that the OneStep-1 and OneStep-2 Phase 3 clinical trials of Locilex (pexiganan cream 0.8%) in patients with mild infections of diabetic foot ulcers (Mild DFI) did not meet the primary clinical endpoint of superiority versus vehicle plus standardized wound care and also did not show any meaningful difference in wound closure rate between the Locilex arm and the vehicle arm in each study. Neither trial met the secondary endpoint of demonstrating a higher rate of eradication of bacteria for the Locilex arm. While the overall adverse event incidence was comparable to vehicle alone, serious adverse events with Locilex included higher than anticipated osteomyelitis and cellulitis in the Locilex arm of each study.

SAExploration Holdings, Inc. (Nasdaq: SAEX) 43.9% HIGHER; announced that it has received approximately $24.4 million of tax credit certificates from the state of Alaskas Department of Revenue. SAE further announced that as a result of receiving these tax credit certificates, and having substantially satisfied the conditional requirements under its senior term loan facility (the Senior Loan Facility), it has been granted access to the remaining $15.0 million of funding available under its Senior Loan Facility.

Corbus Pharma (NASDAQ: CRBP) 16.9% LOWER; was mentioned cautiously in an article by Adam Feuerstein. According to to the report, an unnamed fund manager who is short the stock said the company's only pipeline drug, Resunab, doesn't work.

Under Armour (NYSE: UA) 16% LOWER; reported Q3 EPS of $0.29, $0.04 better than the analyst estimate of $0.25. Revenue for the quarter came in at $1.47 billion versus the consensus estimate of $1.46 billion. sees Q4 revenue up about 20 percent, gross margin relatively unchanged, and operating income in the range of $186 - $191 million. Revenue is expected to be up 20 percent, versus consensus expectations of 22 percent growth. The company is targeting revenue growth consistently in the low-20 percent rage for FY17/FY18. Operating income is expected to be up in the mid-teens range over the next two years. The company says it is on track to achieve revenue of $7.5 billion in FY18.

Calithera Biosciences (NASDAQ: CALA) 15.3% LOWER; Citi initiated coverage with a Sell rating and a price target of $1.00.

Nielsen Holdings (NYSE: NLSN) 14.2% LOWER; reported Q3 EPS of $0.74, $0.02 worse than the analyst estimate of $0.76. Revenue for the quarter came in at $1.57 billion versus the consensus estimate of $1.59 billion. GUIDANCE: Nielsen Holdings sees FY2016 EPS of $2.73-$2.79, versus the consensus of $2.87.

Sonic Corp (NASDAQ: SONC) 11.2% LOWER; reported Q4 EPS of $0.45, $0.01 better than the analyst estimate of $0.44. Revenue for the quarter came in at $162.1 million versus the consensus estimate of $167.15 million. While the macroeconomic environment may impact results, the company expects adjusted earnings per share for fiscal year 2017 to be in the range of down 7% to flat year over year.

Pluristem Therapeutics Inc. (Nasdaq: PSTI) 9% HIGHER; announced it has signed a term sheet for an investment of approximately $30,000,000 by China-based Innovative Medical Management Co., Ltd. (Innovative Medical) (stock code: 002173), a publicly listed Chinese Company active in the healthcare industry and an affiliate of Zheshang Venture Capital Co., Ltd. (ZSVC). ZSVC has ¥ 30 billion yuan ($4.45 billion) under management through more than 30 venture capital, private equity, angel, and buyout funds.

Clayton Williams Energy, Inc. (NYSE: CWEI) 8% HIGHER; announced that it has entered into a definitive purchase and sale agreement with a third party to sell substantially all of the Company's assets in the Giddings Area in East Central Texas for a sale price of $400 million. The sale is subject to customary closing conditions and adjustments. The Company expects to close the sale in December 2016 and use the proceeds from the sale to fund development in the Delaware Basin and repay a portion of its outstanding indebtedness.

Clovis Oncology (NASDAQ: CLVS) 7.5% LOWER; Chardan Capital Markets initiated coverage with a Sell rating and a price target of $15.

Wabash National (NYSE: WNC) 6.4% LOWER; reported Q3 EPS of $0.50, $0.02 better than the analyst estimate of $0.48. Revenue for the quarter came in at $464 million versus the consensus estimate of $479.93 million.

Rambus (NASDAQ: RMBS) 6.3% HIGHER; reported Q3 EPS of $0.16, $0.03 better than the analyst estimate of $0.13. Revenue for the quarter came in at $89.9 million versus the consensus estimate of $86.6 million. GUIDANCE: Rambus sees Q4 2016 EPS of $0.14-$0.18, versus the consensus of $0.15. Rambus sees Q4 2016 revenue of $94-98 million, versus the consensus of $94.4 million.

Swift Transportation (NYSE: SWFT) 6.2% HIGHER; reported Q3 EPS of $0.34, $0.02 better than the analyst estimate of $0.32. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $1.03 billion. Swift Transportation reaffirmed FY2016 guidance.

Baker Hughes (NYSE: BHI) 5.9% HIGHER; reported Q3 EPS of ($0.15), $0.30 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $2.4 billion versus the consensus estimate of $2.41 billion.

ProAssurance Corporation (NYSE: PRA) 5% LOWER; announced preliminary per share results for the third quarter of 2016. We expect to report net income of between $0.61 and $0.65 per diluted share and operating earnings of between $0.43 and $0.47 per diluted share when we release final third quarter results on November 2, 2016. We believe gross premiums written in the quarter will be approximately $230 million and net earned premium for the quarter will be approximately $185 million. We expect our consolidated combined ratio to be in a range between 92% and 94% for the quarter. *** The Street sees Q3 EPS of $0.60.

Electronics for Imaging (NASDAQ: EFII) 3.7% LOWER; reported Q3 EPS of $0.58, in-line with the analyst estimate of $0.58. Revenue for the quarter came in at $245.6 million versus the consensus estimate of $247.35 million.

Blackbaud, Inc. (NASDAQ: BLKB) 3.5% HIGHER; announced that it increased its full-year operating cash flow expectations for 2016 as a result of its early adoption of ASU 2016-09, Compensation - Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting (ASU 2016-09). The Company now expects its full-year cash flow from operations for 2016 to be $147.0 million to $157.0 million, up from $135.0 million to $145.0 million previously, and reaffirmed its previously announced non-GAAP revenue, non-GAAP income from operations, non-GAAP operating margins and non-GAAP diluted earnings per share expectations for 2016.

Procter & Gamble (NYSE: PG) 3.2% HIGHER; reported Q1 EPS of $1.03, $0.05 better than the analyst estimate of $0.98. Revenue for the quarter came in at $16.5 billion versus the consensus estimate of $16.49 billion.

New Mountain Finance Corporation (NYSE: NMFC) 3% LOWER; announced today that it has commenced an underwritten offering of 5,000,000 shares of its common stock. In connection with the proposed offering, the Company intends to grant the underwriters for the offering an option to purchase up to an additional 750,000 shares of the Company’s common stock.

Corelogic (NYSE: CLGX) 2.8% HIGHER; reported Q3 EPS of $0.73, $0.07 better than the analyst estimate of $0.66. Revenue for the quarter came in at $523.9 million versus the consensus estimate of $502.4 million. GUIDANCE: CoreLogic expects to achieve the upper ends of its previously issued 2016 financial guidance. Corelogic sees FY2016 EPS of $2.20-$2.30, versus the consensus of $2.28. Corelogic sees FY2016 revenue of $1.89-1.92 billion, versus the consensus of $1.91 billion.

United Technologies (NYSE: UTX) 2.6% HIGHER; reported Q3 EPS of $1.76, $0.09 better than the analyst estimate of $1.67. Revenue for the quarter came in at $14.4 billion versus the consensus estimate of $14.27 billion. GUIDANCE: United Technologies sees FY2016 EPS of $6.55-$6.60, versus the consensus of $6.58.

Knowles (NYSE: KN) 2.6% LOWER; reported Q3 EPS of $0.37, $0.07 better than the analyst estimate of $0.30. Revenue for the quarter came in at $243.1 million versus the consensus estimate of $233.11 million. GUIDANCE: Knowles sees Q4 2016 EPS of $0.29-$0.35, versus the consensus of $0.34. Knowles sees Q4 2016 revenue of $225-245 million, versus the consensus of $245.63 million.

Allison Transmission (NYSE: ALSN) 2.5% HIGHER; reported Q3 EPS of $0.27, $0.02 better than the analyst estimate of $0.25. Revenue for the quarter came in at $434 million versus the consensus estimate of $431.72 million.

Carrizo Oil & Gas, Inc. (Nasdaq: CRZO) 1.2% LOWER; agreed to acquire Eagle Ford Shale properties from an affiliate of Sanchez Energy Corporation (NYSE: SN) for $181 million in cash, subject to customary closing adjustments. Additionally, Carrizo is providing estimated third quarter production. Commenced an underwritten public offering of 5,000,000 shares of its common stock.

Nutanix (NASDAQ: NTNX) 1% HIGHER; Wall Street launches mostly bullish coverage.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

Citi, Earnings, Pre-Open Losers, Pre-Open Winners, Chardan Capital Markets, Definitive Agreement, Pre Market Movers, Adam Feuerstein

Add Your Comment